Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting | ||
By: GlobeNewswire - 04 Mar 2024 | Back to overview list |
|
– Late-breaking oral presentation to highlight efficacy and safety of ESK-001 in a Phase 2 clinical trial and open label extension (OLE) study in adults with moderate-to-severe plaque psoriasis (STRIDE) – – Additional Phase 1 poster presentation to describe pharmacokinetic and pharmacodynamic characteristics of ESK-001 in healthy participants – – The Company will host a virtual investor event following the Phase 2 data presentation – SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced two clinical data presentations at the American Academy of Dermatology Annual Meeting taking place March 8-12, 2024, in San Diego, CA. Details regarding the presentations are as follows: Oral Presentation E-Poster Presentation Alumis will also host a virtual investor event to review the ESK-001 Phase 2 clinical data being presented at AAD on March 9 at 5:00 p.m. PT. To access the live webcast, please register by visiting the Events page on the Alumis website. About Alumis Alumis Contact Information |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |